BMS
BMS’ investigational psoriasis drug hits primary endpoint in skin clearance at Phase 2
September 12, 2018Research and Development BMS, BMS-986165, Bristol-Myers Squibb, pharma, psoriasis
Bristol-Myers Squibb has unveiled new Phase 2 data for its investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, known as …
BMS’ Opdivo fails to win over NICE as adjuvant melanoma therapy
September 10, 2018Sales and Marketing BMS, NHS, NICE, melanoma, opdivo, pharma
Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an …
Bristol-Myers Squibb appoints Christopher Boerner as new Executive Vice President and Chief Commercial Officer
August 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, bristol myers squibb, cco, chief commercial officer, christopher boerner, executive vice president, murdo gordon
Bristol Myers Squibb has announced that Dr Christopher Boerner will take over from Murdo Gordon as executive Vice President and …
NICE turns down BMS’ blockbuster Opdivo for urothelial carcinoma
July 5, 2018Sales and Marketing BMS, Bristol-Myers Squibb, NICE, opdivo, pharma, urothelial carcinoma
Just in time for the NHS’ 70th birthday, UK watchdog NICE has announced that it has taken the decision to …
BMS’ Opdivo becomes first immuno-oncology agent available in China
June 18, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma
Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …
“Underwhelming” drug data devastates Nektar, shares fall by 42%
June 5, 2018Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma
Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …
New cancer clinical trial model promises to cut costs and development time
May 15, 2018Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, Cancer, MD AndersonCancer Center, clinical trials, pharma
Researchers from the University of Texas MD Anderson Cancer Center have been developing and testing a new model for the …
Top Ten most popular articles on Pharmafile.com this week
May 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia
It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …
BMS pulls the plug on Phase 3 trials of IDO1 inhibitor
May 2, 2018Research and Development BMS, Bristol-Myers Squibb, IDO1, opdivo, pharma, phase 3
Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor acquired through its $800 million acquisition …
The May 2018 issue of Pharmafocus is now live!
April 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, MSD, Pharmafocus, Shire, Takeda, flypharma, keytruda, mhealth, mobile health summit, opdivo, pharma, sugar tax
Just in time for the first good weather of the year, the May 2018 edition of Pharmafocus is available to …
Novartis snatches Amgen and BMS veteran for CMO and Drug Development Head
April 19, 2018Medical Communications Amgen, BMS, Bristol-Myers Squibb, Novartis, appointment, pharma
Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, …
BMS’ Opdivo+Yervoy combo secures FDA approval in kidney cancer
April 18, 2018Research and Development, Sales and Marketing BMS, Bristol Myers Swuibb, Cancer, FDA, Yervoy, carcinoma, opdivo, pharma
The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers …
Top Ten most popular articles on Pharmafile.com this week
March 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, BMS, Biocon, Martin Shkreli, Novartis, Right to try, US, pharma, top ten
Another week goes by, and we may have finally reached Spring here in the UK. Friday means its time for …
BMS restructure will transfer 90 jobs from NY state to Massachusetts and New Jersey
March 15, 2018Manufacturing and Production BMS, Bristol-Myers Squibb, Massachusetts, New York, new jersey, pharma
Bristol-Myers Squibb has announced plans to relocate around 90 roles from the state of New York to facilities in Massachusetts …
BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression
February 6, 2018Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
